Alnylam Pharmaceuticals Inc annual revenue for fiscal TTM was $4.3 billion, an increase of 15.4% from $3.7 billion in fiscal 2025. All figures are reported results from public filings — no estimates or projections.
| Revenue (annual) | TTM → 2026-03-31 | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 | 2020-12-31 | 2019-12-31 | 2018-12-31 | 2017-12-31 | 2016-12-31 | 2015-12-31 | 2014-12-31 | 2013-12-31 | 2012-12-31 | 2011-12-31 | 2010-12-31 | 2009-12-31 | 2008-12-31 | 2007-12-31 | 2006-12-31 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Total Revenue | $4.3B | $3.7B | $2.2B | $1.8B | $1.0B | $844M | $493M | $220M | $75M | $90M | $47M | $41M | $51M | $47M | $67M | $83M | $100M | $101M | $96M | $51M | $27M |
USD; $M / $B as marked. Newest period first. Source: public company filings (via Yahoo Finance aggregation).
| Revenue (quarterly) | 2026-03-31 | 2025-12-31 | 2025-09-30 | 2025-06-30 | 2025-03-31 | 2024-12-31 | 2024-09-30 | 2024-06-30 |
|---|---|---|---|---|---|---|---|---|
| Total Revenue | $1.2B | $1.1B | $1.2B | $774M | $594M | $593M | $501M | $660M |
USD; $M / $B as marked. Newest period first. Source: public company filings (via Yahoo Finance aggregation).
More ALNY metrics: Gross Profit · Operating Income · Net Income · EPS · EBITDA · Free Cash Flow · Shares Outstanding
All ALNY financial statements → Interactive ALNY charts →
About TickerBase · Data methodology & sources